# A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

> **NCT05198752** · PHASE1 · UNKNOWN · sponsor: **Stemirna Therapeutics** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Neoantigen mRNA Personalised Cancer SW1115C3

## Key facts

- **NCT ID:** NCT05198752
- **Lead sponsor:** Stemirna Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-18
- **Primary completion:** 2023-12-22
- **Final completion:** 2024-06-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05198752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05198752, "A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05198752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*